145P Preliminary results of a phase Ⅱ study of fruquintinib combined with sintilimab and chemotherapy as the first-line treatment in advanced naive EGFR- and ALK-negative non-squamous non-small cell lung cancer (nsq-NSCLC). (December 2022) - Shu, Y.; Ma, P.; Shen, H.; Gao, W.; Chen, X.; Sun, J.; Xu, L.